Skip to main content

Japanese NGS Firm Quantum Bio Raises $20M

NEW YORK(GenomeWeb) – Japanese next-generation sequencing technology firm Quantum Biosystems has raised ¥2.4 billion ($20 million) to continue development of its DNA/RNA sequencer.

The Series B funding comes from new investors Innovation Network Corporation of Japan and Mitsubishi UFJ Capital, as well as existing investors JAFCO, UTEC, and Mizuho Capital, the firm said. 

Founded in 2013 and based in Osaka, Quantum Bio is developing single-molecule electronic DNA sequencing technology. The technology measures tunneling currents from DNA bases as the molecule passes by a sub-nanometer gap. It relies on a pair of nanoelectrodes separated by a sub-nanometer gap, across which it places a bias voltage. It then detects changes in the tunneling current as single-stranded DNA or RNA translocates through the gap. 

Quantum Bio told GenomeWeb last year that it was developing a next-generation of the technology that uses a gating nanopore to confine the motion of translocating DNA. Its founders are Toshihiko Honkura, now Quantum Bio's president and CEO, and Masateru Taniguchi, the company's CSO.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.